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An 80-year-old man with a history of gastric cancer and pulmonary emphysema underwent a distal gastrectomy for
gastric cancer in 1997. In 2010, an endoscopic examination revealed a depressed-type lesion at the oral side of the
anastomosis, which was diagnosed as signet-ring adenocarcinoma. Surgical management was considered, but was
rejected because of obstructive and restrictive respiratory events. Chemotherapy was terminated because of adverse
events. Endoscopy was used to administer intratumoral injections of dendritic cells (DCs) targeting synthesized peptides
of Wilms tumor 1 (WT1) and mucin 1, cell-surface associated (MUC1). An immunohistochemical analysis of the tumor
samples indicated positivity for WT1 and MUC1. One month after seven cycles of DC had been administered (between
November 2010 and April 2011), no suspicious lesions were evident, and his biopsy results were normal. The patient
has been in remission for 30 months. Intratumoral injections of DCs showed therapeutic effects in this patient, who
could not undergo endoscopic submucosal dissection or surgery.
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Gastric cancers are the second most common cause of
cancer-related deaths worldwide [1]. Although surgery is
the definitive treatment for gastric cancers, alternative
therapeutic modalities include endoscopic submucosal
dissection (ESD), chemotherapy, and radiation therapy.
Recently, it has been reported that half of all malig-
nancies occur in patients aged over 70 years [2]. Chronic
obstructive pulmonary disease (COPD), which is charac-
terized by airflow limitation, is also common in elderly
individuals [3]. In some cases, standard therapy for malig-
nancies is not suitable because of the presence of COPD.
Sakai et al. [4] showed that COPD was an independent
risk factor for intra- and post-operative pulmonary events.
In addition, Dimopoulou et al. [5] reported that some* Correspondence: m2nagaya@marianna-u.ac.jp
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unless otherwise stated.anti-cancer drugs induce pulmonary toxicity. For example,
paclitaxel, docetaxel, and irinotecan have been reported to
cause non-specific interstitial pneumonitis. In some cases,
minimally invasive therapy might be required for elderly
patients with COPD.
Dendritic cells (DCs) are antigen-presenting cells that
are specialized for the initiation of T-cell immunity [6,7].
DC-based immunotherapy that targets synthesized pep-
tides has recently been used for various malignancies, in-
cluding gastric cancer [8-11]. The appropriate selection of
synthesized peptides is necessary to enhance the thera-
peutic effect of DC-based immunotherapy for gastric
cancer. In 2009, the cancer antigen prioritization project
of the National Cancer Institute ranked Wilms tumor 1
(WT1) and mucin 1, cell-surface associated (MUC1) as
the highest and second highest priority antigens, re-
spectively [12]. As determined by immunohistochemistry
(IHC), the expressions of WT1 and MUC1 in gastric
cancers were found to be 42 to 53% [13] and 93% [14],
respectively.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a potential favorable option [15]. We used esophagogas-
troduodenoscopy (EGD) to administer intratumoral injec-
tions of DCs pulsed with WT1 and MUC1.
Case presentation
An 80-year-old man with a history of gastric cancer and
pulmonary emphysema underwent a Billroth I distal
gastrectomy for early gastric cancer in 1997. In 2005 and
2009, he was referred for an endoscopic mucosal resection
of local gastric cancer recurrence (well-differentiated tubu-
lar adenocarcinoma). In May 2010, he underwent a follow-
up EGD that revealed a depressed-type lesion (10 × 18 mm
in size) on the body of stomach near the anastomosis (O)
(Figure 1a). A histopathological analysis of the biopsy sam-
ples revealed signet-ring adenocarcinoma (Figure 2a-a”).
A computed tomography scan revealed no metastasis.
Although total resection of the gastric remnant is a po-
tentially curative therapy, this surgery was not performed
in consideration of the patient’s lung dysfunction, which
included obstructive and restrictive pulmonary disease
(vital capacity (VC): 2.12 L; %VC: 71.9%; forced expiratory
volume in 1.0 seconds: 42.9%). The patient had a 50-year
history of smoking. ESD was contraindicated because the
cancer was of an undifferentiated type. Therefore, treat-
ment with TS-1 (tegafur, gimeracil, and oteracil potassium;
Taiho Pharmaceutical Co, Ltd, Tokyo, Japan) was initiated
in August 2010. Four weeks after TS-1 administration,
treatment-related anorexia (grade 2; Common Terminology
Criteria for Adverse Events, version 4.0) was observed, and
hence, chemotherapy was discontinued at the request of
the patient.
The methods that were used for DC preparation have
been described previously [16]. The DCs were pulsedFigure 1 Esophagogastroduodenoscopy (EGD) images. (a, b) Type 0-IIc
anastomotic region (O) before vaccination (a). The gastric cancer regresse
(b). Arrows indicate the location of the cancer.with major histocompatibility complex (MHC)-I-restricted
WT1 peptide antigens, according to the patient’s hu-
man leukocyte antigen (HLA)-A pattern (HLA-A 2402;
CYTWNQMNL (mutant WT1 peptide, Neo-MPS, San
Diego, California, United States) and MUC1 long peptide (30
mer at 20 mg/mL; TRPAPGSTAPPAHGVTSAPDTRPAP-
GSTAP; Greiner Japan, Tokyo, Japan)). The DCs were
characterized using flow cytometry to ensure that they
achieved the typical phenotype of mature DCs. The sur-
face molecules that were expressed by the DCs were
determined. The phenotype CD14–/low/HLA-DR+/HLA-
ABC+/CD80+/CD83+/CD86+/CD40+/CCR7+ was consid-
ered to define mature DCs. The DCs were cryopreserved
until the day of administration. The DC suspension was
adjusted to a total volume of 1.0 mL with saline.
Six months after the gastric cancer recurrence had been
diagnosed, intratumoral injections of DCs were adminis-
tered using EGD between November 2010 and April 2011.
This treatment was approved by the institutional review
board of Isoukai (approval number: 26–1) and was con-
ducted in accordance with the Declaration of Helsinki.
Vaccinations were repeated seven times at two to eight-
week intervals (approximately 2.99 × 107 cells/injection; the
first four vaccinations at two-week intervals and the last
three vaccinations at four- to eight-week intervals). A nee-
dle was used (diameter 25 G, length 4 mm) to administer
DCs at four submucosal layer sites around the tumor.
Subsequently, we administered OK432 (1-3KE) dissolved
in 0.5 mL saline at two sites in the submucosal layer
around the tumor. DC therapy was well tolerated and the
only treatment-related adverse event was fever, with a
body temperature of over 38°C for two days after the
fourth vaccination. One month after the final admin-
istration, the gastric cancer was found to have regressedlesion (10 × 18 mm in size) on the body of the stomach near the
d to an obscure lesion one month after the final cycle of treatment
Figure 2 Histological analysis of the biopsy sample. Hematoxylin and eosin (H & E) staining (a-a”, f-f”) and immunohistochemistry of serial sections
of tissues for Wilms tumor 1 (WT1) (b-b”, g-g”) and mucin 1, cell-surface associated (MUC1) (c-c”, h-h”). (a-a”, f-f”) H & E staining before and
after vaccination. H & E staining showing signet-ring cells in tissue before vaccination (a-a”). One month after the final administration, pathological
examination revealing normal luminal epithelial cells (f-f”). (b-b”, g-g”) Staining for WT1 before and after vaccination. Samples positive for
WT1 in approximately 60% of the cells before vaccination at the tumor site (b-b”) and the remarkable reduction in WT1 positivity confirmed
after vaccination (g-g”). (c-c”, h-h”) Staining for MUC1 before and after vaccination. Approximately 70% of tumor cells were positive for MUC1 before
vaccination (c-c”) and MUC1 staining was observed in normal glands only after vaccination (f-f”). Immunohistochemical staining of CD4+ and
CD8+ T-cells in the biopsy samples. Serial sections of the tissues used for H & E staining prepared and stained for CD4 and CD8 (d, e, i, j). (d-d”, i-i”)
Staining for CD4 before (d-d”) and after vaccination (i-i”). (e-e”, j-j”) Staining for CD8 before (e-e”) and after vaccination (j-j”). CD4+ and CD8+ T-cells
observed more frequently in normal gastric tissues after vaccination than had been observed in tumor tissues before vaccination. (Magnification:
a-j 4×, a’-j’ 10×, a”-j” 20×).
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of the biopsy samples revealed no signet-ring cells
(Figure 2f-f”). During the 30 months following DC-
based immunotherapy, no pathological recurrence has
been observed. Laboratory data indicated reductions incarcinoembryonic antigen and carbohydrate antigen
19–9 levels after DC therapy, which decreased from
8.2 to 6.8 ng/mL (normal range: <5.0 ng/mL) and from
33.2 to 24.7 U/mL (normal range: <37.0 U/mL),
respectively.
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Carpinteria, California, United States) [13] and MUC1
(Becton Dickinson Labware; Franklin Lakes, New Jersey,
United States) was performed as previously described
[17], with a few modifications. IHC results were positive
for WT1 in approximately 60% of signet ring cells before
vaccination (Figure 2b-b”); however, the number of cells
staining positive was remarkably reduced after vaccination
(Figure 2g-g”). Approximately 70% of cells were positive
for MUC1 before vaccination (Figure 2c-c”). After vaccin-
ation, remodeling was confirmed at the site of malignant
cells, and MUC1 positivity was observed only in the
normal glands (Figure 2h-h”).
No increases in the proportions of CD4+ and CD8+ T-
cells were noted in the peripheral blood, based on assess-
ments performed before and after vaccination (CD4+ T-
cells: 43.9 to 42.5%; CD8+ T-cells: 29.3 to 25.5%). On the
other hand, CD4+ and CD8+ T-cells were observed more
frequently in the normal gastric tissue after vaccination
(Figure 2i-i”, j-j”) than they had been observed in the
tumor tissues before vaccination (Figure 2d-d”, e-e”).
The frequency of WT1-specific cytotoxic T lymphocytes
(CTLs) increased from 0.03 to 0.08%. The method used has
been described in our previous report [16]. At 31 months
after the final vaccination, the levels of WT1-specific CTLs
remained high (0.10%) (Figure 3a-c).
Discussion
In this case, restrictive pulmonary disease led the primary
oncologist to opt for chemotherapy instead of surgery.
However, the patient developed intolerable chemotherapy-
associated anorexia, which necessitated the discontinu-
ation of treatment. Since a few previous studies have
indicated that DC immunotherapy could be safely ad-
ministered to cancer patients as a minimally invasive treat-
ment [8,9,18], we chose this therapy for our patient. The
direct injection of DCs into tumors has been investigated
in clinical studies, including those on hepatoma [19], pan-
creatic cancer [20], and gastric cancer [21]. Wen et al. [22]Figure 3 Analysis of Wilms tumor 1 (WT1)-specific cytotoxic T lymphocy
after the final vaccination. WT1-specific CTL levels before vaccination increased
the final vaccination, WT1-specific CTL levels increased to 0.10% (c).compared the therapeutic immunity achieved by several
modes of DC injection, including intratumoral, intranodal,
intravenous, and subcutaneous injections in mice. The
survival rates were dramatically increased by vaccination
via intratumoral injection, as compared with injections
performed using other delivery methods. Pellegatta et al.
[23] reported that, in comparison with other delivery
methods, intratumoral injection of DCs may increase anti-
tumor efficacy by altering the intratumoral environment
and increasing T-cell-mediated immune responses. In this
case, increased WT1-specific CTL levels were observed
after DC immunotherapy, indicating that the DCs pre-
sented WT1 to naïve CD8+ T-cells in a precise manner.
We suggest that gastric cancer could be a good indication
for the direct injection of DCs and that the appropriate
site for injection can be selected using live imaging with
EGD.
Immature DCs were used for direct injections in previ-
ous studies because their phagocytic ability has been con-
sidered to be superior to that of mature DCs [24]. However,
immature DCs have been shown to induce tolerance and
the antigen-specific inhibition of effector T-cell function
[25,26]. Drutman and Trombetta [27] showed that mature
DCs retained a robust capacity to capture soluble antigens.
Furthermore, antigens internalized by mature DCs were
efficiently presented on MHC class II cells and cross-
presented on MHC class I cells. De Vries et al. [28]
demonstrated that mature DCs efficiently migrate into
T-cell-populated areas of the lymph nodes of melanoma
patients. Taken together, these findings suggest that it
might be reasonable to use mature DCs for direct injec-
tions into tumors.
IHC results for WT1 and MUC1 indicated significant
changes after vaccination. Mucin is a high molecular weight
glycoprotein that plays an important role in protecting the
gastrointestinal tract epithelium and is normally present in
abundance on the luminal surface of various secretory
epithelial cells. The core peptides in the tandem repeat
domain are masked in normal cells and exposed in cancertes (CTLs). (a) Before vaccination. (b) After vaccination. (c) At 31 months
from 0.03 (a) to 0.08% at the final vaccination (b). At 31 months after
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cancer cells with exposed tandem repeat domains [29].
In this case, MUC1-positive cells were present on the
surface of the signet-ring adenocarcinoma before vaccin-
ation (Figure 2c-c”); however, MUC1-positive cells were
only confirmed on normal luminal epithelial cells after DC
immunotherapy, as we had expected (Figure 2h-h”).
Conclusions
To the best of our knowledge, this is the first report on the
therapeutic effects of DCs that target synthesized peptides
in a patient with gastric cancer who could not undergo
ESD or curative surgery.
Consent
We provided precise explanations of the therapy to the
patient and his family. They gave written informed con-
sent for the publication of this case report and any ac-
companying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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